Subject: PSID Publishes White Paper and Data on its Successful Detection of Zika Virus

SCV Client Spotlight
BY READING THIS EMAIL YOU CERTIFY YOU HAVE READ THE DISCLAIMER BELOW AND THE FULL DISCLAIMER PROVIDED THROUGH A LINK AT THE END OF THIS EMAIL. This is a paid advertisement. SmallCapVoice.com, Inc. is not responsible or held liable for the information in the press releases issued by the companies in these emails. Please always do your own due diligence.
Facebook Twitter YouTube
PSID Publishes White Paper and Data on its Successful Detection of Zika Virus
Hot Stock to WatchHot Stock to Watch

Company: PositiveID Corporation (OTCQB: PSID)


Last:

Price: 0.0024

Change (%): + 0.0007 (39.82)

Volume: 37,810,825
PSID Chart

PositiveID Corporation Publishes White Paper and Data on its Successful Detection of Zika Virus

DELRAY BEACH, Fla., Nov. 16, 2016 (GLOBE NEWSWIRE) - PositiveID Corporation (“PositiveID” or “Company”) (OTCQB:PSID), a life sciences company focused on detection and diagnostics, announced today that it has published a white paper and data on its successful detection of the Zika virus on its Firefly Dx polymerase chain reaction (“PCR”) breadboard prototype pathogen detection system (“prototype system”). The white paper can be found in the Research and White Papers section of PositiveID’s website or by clicking here.

PositiveID used GenArraytion Inc.’s Aedes Aegypti MultiFLEX™ PCR test, which targets four genetic regions of the Zika virus, on PositiveID’s Firefly Dx prototype system. PositiveID is developing the Firefly Dx prototype system to be a handheld, fully automated, lab quality device able to detect bio-threats at the point of need in less than 30 minutes. Currently, PCR tests are run on large lab equipment and take a minimum of four hours to deliver results. A design advantage of Firefly Dx is that it does not require additional equipment or separate steps for sample preparation and purification, unlike current lab-based equipment, thus reducing time to results as well as cost per test. In addition, there is significantly less chance of sample contamination compared to existing testing methods.

“Testing for Zika virus and other disease outbreaks quickly and cost-effectively at the point of need is critical for stopping further transmission,” stated William J. Caragol, Chairman and CEO of PositiveID. “Unfortunately, as is often the case, because lab-based testing demands both significant time and financial resources, many people are not being tested at the point of need, allowing the spread of an infection to continue.”

Zika is a fever-causing virus transmitted by the Aedes Aegypti mosquito that can cause microcephaly, a serious congenital condition in which babies are born with head and brain abnormalities, and Guillain-Barre syndrome, a rare neurological disorder that can result in paralysis.

Continue Reading

Like Us on FacebookFollow Us on Twitter

IMPORTANT DISCLAIMER - PLEASE READ THOROUGHLY
SmallCapVoice (SCV) is an electronic publication. Information sources for our profiles include, but are not limited to, online research, member suggestions, magazines, newspapers, analyst suggestions, publicly available material information provided by the profiled company, press releases and similar sources. This communication is not an offer to sell or a recommendation that you buy or sell any security. SCV holds no securities licenses and is not qualified to provide investment advice. We are compensated for these advertisements by the profiled companies. You should not use this newsletter as the sole basis for any investment decision. While all investments involve risk, microcap stocks are among the most risky. Many microcap companies have no proven track record. You should only invest in microcap companies if you can afford to lose your entire investment. You should consult a qualified, licensed financial advisor or stock broker before making any decisions to invest in the securities of any company that is described in these profiles. These profiles are paid advertisements. Although we have a reasonable belief that the information in each profile is accurate, we cannot guarantee that this information, which originates from third parties, is accurate. We do not have the resources to confirm the accuracy of all information obtained from third parties. It is important for you to verify all information by your own independent research. You are receiving this message because you have agreed to receive emails from SmallCapVoice.com. You may opt out of our distribution list at any time by clicking on the “unsubscribe” link below. Link to full disclosure about compensation paid to SmallCapVoice.com, Inc. by companies featured on our website or in our e-mail communications.

About Penny Stocks